MADIT-II: ICD when ejection fraction is 30%. (Randomized Trial Halted Early).(Multicenter Automatic Defibrillator Implantation Trial-II)
Publication: Internal Medicine News
Publication Date: 15-FEB-02
Author: Jancin, Bruce
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
SNOWMASS, COLO. -- Indications for implantable cardioverter defibrillator therapy will be expanded and simplified as a result of the recently halted Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II), Dr. Roger A. Winkle predicted at a conference sponsored by the American College of Cardiology.
The message of MADIT-II is that all patients with coronary heart disease and a left ventricular ejection fraction of 30% or less should receive a prophylactic implantable cardioverter defibrillator (ICD) regardless of whether or not they've had syncope or a life-threatening arrhythmia.
The...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
